News

Funds Benefit Cancer Research in N.C. and Beyond

Nurses now have a wealth of new and updated resources to ensure their patients with prostate cancer can make the best treatment choices they can, thanks to the Prostate Cancer

Through her Bravery Bags program, Harding Cranford brings together members in the healthcare setting and the community to brighten patients’ days.

Investigators are working on expanding immunotherapy use for this patient population, and genetic testing will be more important than ever.

Compared to the general population, survivors of childhood cancer who live 5 or more years from diagnosis are at a higher risk for skin cancer.

Two new urine tests currently being investigated for bladder cancer detection and monitoring have demonstrated more than 90% sensitivity and specificity – highlighting the potential for addressing an unmet need among this patient population.

This was the first large, randomized clinical trial to show that diet can reduce the risk of dying from breast cancer.

Lenalidomide (Revlimid) significantly reduced the risk for smoldering multiple myeloma to progress to cancer among patients with moderate to high risk, according to findings from the phase II/III E3A06 trial to be presented at the 2019 ASCO Annual Meeting.

A group of researchers in the UK sought out to determine the efficacy of a reduced-dose regimen of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in this patient population through the randomized, phase III GO2 clinical trial.

The FDA has approved the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) for the frontline treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In this month's episode, we'll hear from one extraordinary oncology nurse who ran 100 miles for cancer research.

The FDA approved the combination use of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma.

While the FDA currently has no plans to ban textured breast implants, the agency did outline steps to ensure providers and patients are educated on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

The anti-vaccination movement is causing outbreaks around the world, and may be even more dangerous for patients with cancer.

Children with severe sensorineural hearing loss (SNHL) from brain tumor treatment demonstrated greater reading difficulties compared with those who experienced mild or no hearing loss.

Event Supports Research through the V Foundation

When it comes to the treatment of patients with nonmetastatic castration-resistant prostate cancer (M0CRPC), 3 pivotal trials—SPARTAN, PROSPER, and most recently, ARAMIS—have demonstrated the safety and efficacy of second-generation targeted antiandrogens, said Richard (Rick) JaeBong Lee, MD, PhD.

While Lynch syndrome may be more common than originally thought, research continues to move forward to improve the outcomes of this patient population.

The FDA approved ramucirumab (Cyramza) as a single-agent treatment for patients with hepatocellular carcinoma (HCC) with an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib (Nexavar).

Nivolumab plus radiation did not improve overall survival compared to temololomide in patients with newly diagnosed glioblastoma.

Chemotherapy-induced peripheral neuropathy affects the daily activities of patients and survivors, but nurses can be key players in helping patients who develop the condition.

The Food and Drug Administration granted leronlimab a fast track designation for the treatment of patients with metastatic triple-negative breast cancer.

Healthcare providers of all disciplines should work together to educate individuals about the symptoms of colorectal cancer.

We asked patients, survivors, and caregivers to give their oncology nurses a shout out. Here's what they had to say.

Generous Donor to Match Every Donation up to $100,000 to the Tyler Trent Fund

Funds Raised to Support Cancer Research in Virginia, Nationwide

The FDA approved ado-trastuzumab emtansine for the treatment of HER2-positive early breast cancer, after it showed a 50% decrease of disease or death compared with trastuzumab.

The FDA has approved a supplemental new drug application (sNDA) for ivosidenib (Tibsovo) as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia (AML), as detected by an FDA-approved test, who are ≥75 years old or are ineligible to receive intensive chemotherapy.

The HPV vaccine is commonly associated with preventing cervical cancer, but it plays a major role in oral cancers, too.

Here are the top 5 Oncology Nursing News stories for April 2019.